Modulation of immune responses with transcutaneously deliverable adjuvants

Vaccine

Volumn 22, Issue 19, 2004, Pages 2385-2390

  Partidos, Charalambos D ^a   Beignon, Anne Sophie ^a,b   Briand, Jean Paul ^a   Muller, Sylviane ^a  

^a CNRS   (France)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CpG motifs; Enterotoxins; LT mutants; Peptides; Transcutaneous immunisation

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; BACTERIAL TOXIN; CHOLERA TOXIN; CYTOKINE; EXOTOXIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OLIGODEOXYNUCLEOTIDE;

ANTIGEN SPECIFICITY; BACTERIAL STRAIN; CELL DIFFERENTIATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CPG ISLAND; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; INFECTION; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; SKIN; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANTIBODY FORMATION; IMMUNITY, CELLULAR; PEPTIDES; VACCINES;

EID: 2942558653     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.063     Document Type: Conference Paper

References (35)

1. Streilein W.J. Skin-associated lymphoid tissues (SALT): origins and functions. J. Invest. Dermatol. 80:1983;12s-16s
2. Williams I.R., Kupper T.S. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci. 58:1996;1485-1507
3. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:2000;1403-1406
4. Hammond S.A., Guebre-Xabier M., Yu J., Glenn G.M. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit. Rev. Ther. Drug Carrier Syst. 18:2001;503-526
5. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145-173
6. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature. 391:1998;851
7. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C.R., Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:2000;5306-5313
8. Glenn G.M., Scharton-Kersten T., Vassell R., Mallett C.P., Hale T.L., Alving C.R. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:1998;3211-3214
9. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 102:2001;344-351
10. Godefroy S., Goestch L., Plotnicky-Gilquin H., Nguyen T.N., Schmitt D., Staquet M.J., et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). Vaccine. 21:2003;1665-1671
11. Hammond S.A., Walwender D., Alving C.R., Glenn G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine. 19:2001;2701-2707
12. + T cells. Immunology. 105:2002;204-212
13. Kahlon R., Hu Y., Orteu C.H., Kifayet A., Trudeau J.D., Tan R., et al. Optimization of epicutaneous immunization for the induction of CTL. Vaccine. 21:2003;2890-2899
14. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microb. Rev. 56:1992;622-647
15. Anjuere F., George-Chandy A., Audant F., Rousseau D., Holmgren J., Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J. Immunol. 170:2003;1586-1592
16. Guebre-Xabier M., Hammond S.A., Epperson D.E., Yu J., Ellingsworth L., Glenn G.M. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77:2003;5218-5225
17. Baba T., Hanada K., Hashimoto I. The study of ultraviolet B-induced apoptosis in cultured mouse keratinocytes and in mouse skin. J. Dermatol. Sci. 12:1996;18-23
18. Bektas M., Orfanos C.E., Geilen C.C. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol. Biol. 46:2000;111-119
19. Bektas M., Dullin Y., Wieder T., Kolter T., Sandhoff K., Brossmer R., et al. Induction of apoptosis by synthetic ceramide analogues in the human keratinocyte cell line HaCaT. Exp. Dermatol. 7:1998;342-349
20. Matsue H., Kobayashi H., Hosokawa T., Akitaya T., Ohkawara A. Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes. Arch. Dermatol. Res. 287:1995;315-320
21. Henseleit U., Rosenbach T., Kolde G. Induction of apoptosis in human HaCaT keratinocytes. Arch. Dermatol. Res. 288:1996;676-683
22. Parr M.B., Kepple L., Parr E.L. Langerhans cells phagocytose vaginal epithelial cells undergoing apoptosis during the murine estrous cycle. Biol. Reprod. 45:1991;252-260
23. Ronchetti A., Rovere P., Iezzi G., Galati G., Heltai S., Protti M.P., et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163:1999;130-136
24. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:2000;423-434
25. Dupuis M., Denis-Mize K., LaBarbara A., Peters W., Charo I.F., McDonald D.M., et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31:2001;2910-2918
26. Pizza M., Giuliani M.M., Fontana M.R., Douce G., Dougan G., Rappuoli R. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. Int. J. Med. Microbiol. 290:2000;455-461
27. Tierney R., Beignon A.-S., Rappuoli R., Muller S., Sesardic D., Partidos C.D. Transcutaneous immunisation with tetanus toxoid and mutants of LT as adjuvants elicits strong protective antibody responses. J. Infect. Dis. I88:2003;753-758
28. + T cells and secrete gamma interferon after coapplication onto bare skin. Infect. Immun. 70:2002;3012-3019
29. Partidos C.D., Beignon A.S., Mawas F., Belliard G., Briand J.P., Muller S. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine. 21:2003;776-780
30. Glenn GM, Transcutaneous immunization. In: Dietrich G, Goebel W, editors. Vaccine delivery strategies. Horizon Scientific Press, 2002, p. 53-81.
31. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. U.S.A. 97:2000;371-376
32. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20:2002;709-760
33. McCluskie M.J., Weeratna R.D., Payette P.J., Davis H.L. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol. Med. Microbiol. 32:2002;179-185
34. Dumais N., Patrick A., Moss R.B., Davis H.L., Rosenthal K.L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 186:2002;1098-1105
35. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76:2002;127-135